Literature DB >> 30837111

Single- or double-anastomosis duodenal switch versus Roux-en-Y gastric bypass as a revisional procedure for sleeve gastrectomy: A systematic review and meta-analysis.

Yung Lee1, Yosef Ellenbogen2, Aristithes G Doumouras3, Scott Gmora3, Mehran Anvari3, Dennis Hong4.   

Abstract

BACKGROUND: Laparoscopic sleeve gastrectomy (SG) is one of the most commonly performed bariatric procedure worldwide. There is currently no consensus on which revisional procedure is best after an initial SG.
OBJECTIVES: To compare the efficacy and safety between single-anastomosis duodeno-ileal bypass (SADI) or biliopancreatic diversion with duodenal switch (BPD-DS) versus Roux-en-Y gastric bypass (RYGB) as a revisional procedure for SG.
SETTING: University Hospital, Canada.
METHODS: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and PubMed were searched up to August 2018. Studies were eligible for inclusion if they compared SADI or BPD-DS with RYGB as a revisional bariatric procedure for SG. Primary outcome was absolute percentage of total weight loss. Secondary outcomes were length of stay, adverse events, and improvement or resolution of co-morbidities (diabetes, hypertension, or hypercholesterolemia). Pooled mean differences were calculated using random effects meta-analysis.
RESULTS: Six retrospective cohort studies involving 377 patients met the inclusion criteria. The SADI/BPD-DS group achieved a significantly higher percentage of total weight loss compared with RYGB by 10.22% (95% confidence interval, -17.46 to -2.97; P = .006). However, there was significant baseline equivalence bias with 4 studies reporting higher initial body mass index (BMI) in the SADI/BPD-DS group. There were no significant differences in length of stay, adverse events, or improvement of co-morbidities between the 2 groups.
CONCLUSION: SADI, BPD-DS, and RYGB are safe and efficacious revisional surgeries for SG. Both SADI and RYGB are efficacious in lowering initial BMI but there is more evidence for excellent weight loss outcomes with the conversion to BPD-DS when the starting BMI is high. Further randomized trials are required for definitive conclusions.
Copyright © 2019 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biliopancreatic diversion with duodenal switch; Revisional bariatric surgery; Roux-en-Y gastric bypass; Single-anastomosis duodeno-ileal bypass; Sleeve gastrectomy

Mesh:

Year:  2019        PMID: 30837111     DOI: 10.1016/j.soard.2019.01.022

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  5 in total

1.  Bridging interventions before bariatric surgery in patients with BMI ≥ 50 kg/m2: a systematic review and meta-analysis.

Authors:  Yung Lee; Jerry T Dang; Noah Switzer; Roshan Malhan; Daniel W Birch; Shahzeer Karmali
Journal:  Surg Endosc       Date:  2019-08-09       Impact factor: 4.584

2.  A safety study of laparoscopic single-anastomosis duodeno-ileal bypass with gastric plication (SADI-GP) in the management of morbid obesity.

Authors:  Istvan Bence Balint; Ferenc Csaszar; Lajos Orban; Peter Radics; Akos Farics; Gergo Manfai; Veronika Hari; Rebeka Javor
Journal:  Langenbecks Arch Surg       Date:  2021-08-17       Impact factor: 3.445

3.  Indications and Long-Term Outcomes of Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass.

Authors:  Antonio D'Urso; Michel Vix; Silvana Perretta; Mihaela Ignat; Louise Scheer; Didier Mutter
Journal:  Obes Surg       Date:  2021-05-01       Impact factor: 4.129

Review 4.  Revisional Surgeries of Laparoscopic Sleeve Gastrectomy.

Authors:  Siyuan Li; Siqi Jiao; Siwei Zhang; Jiangjiao Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2021-02-10       Impact factor: 3.168

5.  Comparing weight loss outcomes after conversion to Roux-en-Y gastric bypass versus duodenal switch from sleeve gastrectomy in a community hospital.

Authors:  Jeremy Jen; Hau Phan; Brett Johnson; Corliann Blyn; Janet Lavrich; Krishna Mallem; Priya Kalsank Pai; Piotr Krecioch
Journal:  Surg Endosc       Date:  2022-10-05       Impact factor: 3.453

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.